Overview

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or GemOx in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Status:
NOT_YET_RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or GemOx in the treatment of relapsed or refractory peripheral T-cell lymphoma
Phase:
PHASE1
Details
Lead Sponsor:
Sun Yat-sen University